Welcome!

News Feed Item

Ncardia unterzeichnet Lizenzvertrag mit dem ersten pharmazeutischen Partner für das Patentportfolio für Krankheitsmodelle

Roche und Ncardia haben eine breite Lizenzvereinbarung getroffen, bei der Roche und ihre Tochtergesellschaften Zugang zu wichtigen Patenten für die Modellierung von Krankheiten von Ncardia erhalten.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: http://www.businesswire.com/news/home/20171013005507/de/

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and dise ...

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modeling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia is providing tools to facilitate accelerated development of drugs, while replacing animal studies and putting a "human" aspect back into drug discovery. (Graphic: Business Wire)

Ncardia wurde vor kurzem durch die Fusion von Axiogenesis und Pluriomics gebildet. Die beiden Unternehmen haben Pionierarbeit bei der Entwicklung von aus Stammzellen abgeleiteten Zellen für Medikamentenentwicklung und Sicherheitspharmakologie geleistet und insbesondere fortgeschrittene Anwendungen in den Bereichen Krankheits- und Gewebe-modellierung.

Das Patentportfolio von Ncardia besteht aus mehreren erteilten Patentfamilien in Europa, den USA und Japan. Die Screening- und Krankheitsmodellierungs-Technologie umfasst nicht nur Patienten-iPSC-Zellen sondern auch die Induktion des Phänotyps durch genetische Manipulation, mRNA- oder siRNA-Transfektion oder durch chemische oder physikalische Induktion.

Dr. Stefan Braam, CEO von Ncardia, kommentierte: "Die Mission von Ncardia ist es, unsere Kunden zu unterstützen und zu befähigen, bessere Medikamente schneller zu entwickeln. Die Kombination von iPSC-abgeleiteten Krankheitsmodellen mit phänotypischem Screening ist eine äußerst effektive Methode zur Identifizierung neuer Wirkstoffkandidaten. Diese Lizenz markiert einen weiteren Schritt in der Technologie-Strategie von Ncardia, um das Potenzial von Stammzell-Anwendungen im Markt für Wirkstoffforschung zu entwickeln. "

Roche hat jetzt eine nicht-exklusive, weltweite Lizenz für die wichtigsten Krankheits-Modellierungspatente von Ncardia erhalten. Die Patente beanspruchen die Verwendung von Krankheitsmodellen unter Verwendung von Stammzell-abgeleiteten Zellen für die Entdeckung und Entwicklung neuer Arzneimittelkandidaten. Die finanziellen Bedingungen der Vereinbarungen wurden nicht offengelegt.

“Diese Lizenz ist der erste Schritt unserer Strategie, unsere Technologie für den Markt für Arzneimittelforschung und -entwicklung zur Verfügung zu stellen." Felix von Haniel VP BD und Vertrieb von Ncardia. Zusätzlich zu den Anwendungen der Krankheitsmodellierung setzt sich Ncardia dafür ein, die prädikativsten gesunden menschlichen Zellmodelle bereitzustellen, um Sicherheitstests zu verbessern und zu beschleunigen.

Ncardia (www.ncardia.com) ist der festen Überzeugung, dass Stammzellentechnologie dazu beitragen wird, bessere Medikamente schneller zum Patienten zu bringen. Das Unternehmen entwickelt, produziert und vertreibt humane Zelltestsysteme mit einer hohen Prädiktivität für die Sicherheitspharmakologische Beurteilung und Wirksamkeitsstudien von Wirkstoffkandidaten. Das kardiale Produktportfolio umfasst eine große Auswahl von hiPSC-abgeleiteten Kardiomyozyten (Pluricyte®, Cor.4U® und vCor.4U®) sowie kardiale Fibroblasten (FibroCor.4U®). Zudem bietet Ncardia mit der CardioplateTM Produktlinie eine „ready-to-use“- Lösung qualitätsgeprüfter Assay-spezifischer Platten an. Das neuronale Zellportfolio enthält pan-neuronale CNS4U, Peri.4U® periphere Neuronen und Astro.4U® Astrozyten.

Ncardia hat sich dazu verpflichtet, seinen Kunden funktionierende Testlösungen durch die Entwicklung eigener Assays und umfangreiche Unterstützung bei bereits bestehenden Assay-Lösungen bereitzustellen. Das Unternehmen verfügt über ein breites Spektrum verschiedener Applikationen und unterschiedlicher Testsysteme, wie etwa Elektrophysiologie-, Biochemie- und Kontraktions-basierte Assays für die prädiktive sicherheitspharmakologische Bewertung von Wirkstoffkandidaten und toxikologische Tests. Zudem bietet Ncardia seine Kunden ein großes Portfolio an Servicedienstleistungen - von Krankheitsmodellen bis zu kardiovaskulären Wirksamkeitsstudien an und entwickelt dieses kontinuierlich weiter.

Ncardia hat Niederlassungen in Belgien, den Niederlanden, Deutschland und den USA. Das Unternehmen ist in privater Hand und wurde nach der Fusion von Pluriomics und Axiogenesis gegründet.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...